Response to: Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Zheng .
作者信息
Viswanathan Vidya Sankar, Khorrami Mohammadhadi, Jazieh Khalid, Fu Pingfu, Pennell Nathan, Madabhushi Anant
机构信息
Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.
Biomedical Engineering, Case Western Reserve Univ, Cleveland, Ohio, USA.
出版信息
J Immunother Cancer. 2022 May;10(5). doi: 10.1136/jitc-2022-005086.
Abstract
摘要
相似文献
1
Response to: Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Zheng .对郑关于《新型成像生物标志物预测接受放化疗和度伐鲁单抗治疗的 III 期不可切除非小细胞肺癌的预后》的通信的回复 。
J Immunother Cancer. 2022 May;10(5). doi: 10.1136/jitc-2022-005086.
2
Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh .关于Jazieh的《新型影像生物标志物预测接受放化疗和度伐鲁单抗治疗的III期不可切除非小细胞肺癌的预后》的通信
J Immunother Cancer. 2022 May;10(5). doi: 10.1136/jitc-2022-004965.
3
Locally Advanced, Unresectable Non-Small Cell Lung Cancer.局部晚期、不可切除的非小细胞肺癌。
Curr Oncol Rep. 2020 Mar 5;22(4):31. doi: 10.1007/s11912-020-0882-3.
4
Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab.接受放化疗和度伐利尤单抗治疗的 III 期非小细胞肺癌的临床结局、局部区域控制和转移导向治疗的作用。
Radiother Oncol. 2020 Aug;149:205-211. doi: 10.1016/j.radonc.2020.04.047. Epub 2020 Apr 30.
5
Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer.在不可切除的 III 期非小细胞肺癌的真实世界患者中，放化疗后使用度伐利尤单抗进行巩固治疗。
Thorac Cancer. 2020 Jun;11(6):1541-1549. doi: 10.1111/1759-7714.13426. Epub 2020 Apr 13.
6
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.免疫检查点抑制剂联合放化疗治疗不可切除 III 期非小细胞肺癌。
Lung Cancer. 2019 Aug;134:259-267. doi: 10.1016/j.lungcan.2019.05.027. Epub 2019 May 29.
7
Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.局部晚期不可切除肺癌管理中的未满足临床需求：改善患者结局的治疗策略。
Adv Ther. 2019 Mar;36(3):563-578. doi: 10.1007/s12325-019-0876-4. Epub 2019 Jan 29.
8
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.durvalumab 联合放化疗治疗不可切除 III 期非小细胞肺癌（PACIFIC）患者的报告结果：一项随机、对照、III 期临床研究。
Lancet Oncol. 2019 Dec;20(12):1670-1680. doi: 10.1016/S1470-2045(19)30519-4. Epub 2019 Oct 7.
9
Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer.不可切除 III 期非小细胞肺癌中使用及妨碍使用度伐利尤单抗巩固治疗的因素。
Radiother Oncol. 2020 Mar;144:101-104. doi: 10.1016/j.radonc.2019.11.015. Epub 2019 Nov 28.
10
Long-term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report.多柔比星联合顺铂同期放化疗治疗肺多形性癌的长期疗效：1 例报告。
Thorac Cancer. 2020 Apr;11(4):1090-1093. doi: 10.1111/1759-7714.13331. Epub 2020 Feb 11.
本文引用的文献
1
Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab.新型影像学生物标志物预测放化疗联合度伐利尤单抗治疗不可切除 III 期非小细胞肺癌的结局。
J Immunother Cancer. 2022 Mar;10(3). doi: 10.1136/jitc-2021-003778.
2
Novel Non-Invasive Radiomic Signature on CT Scans Predicts Response to Platinum-Based Chemotherapy and Is Prognostic of Overall Survival in Small Cell Lung Cancer.CT扫描上的新型非侵入性放射组学特征可预测小细胞肺癌对铂类化疗的反应并对总生存期具有预后价值。
Front Oncol. 2021 Oct 20;11:744724. doi: 10.3389/fonc.2021.744724. eCollection 2021.
3
Radiomics for Survival Risk Stratification of Clinical and Pathologic Stage IA Pure-Solid Non-Small Cell Lung Cancer.基于影像组学的临床和病理ⅠA 期纯磨玻璃密度非小细胞肺癌生存风险分层。
Radiology. 2022 Feb;302(2):425-434. doi: 10.1148/radiol.2021210109. Epub 2021 Nov 2.
4
Radiomics in Oncology: A Practical Guide.肿瘤放射组学：实用指南。
Radiographics. 2021 Oct;41(6):1717-1732. doi: 10.1148/rg.2021210037.
5
Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab.肿瘤程序性死亡受体配体1（PD-L1）表达与接受度伐鲁单抗巩固治疗的Ⅲ期非小细胞肺癌（NSCLC）患者的预后相关。
Transl Lung Cancer Res. 2021 Jul;10(7):3071-3078. doi: 10.21037/tlcr-21-249.
6
Prospective Evaluation of Repeatability and Robustness of Radiomic Descriptors in Healthy Brain Tissue Regions In Vivo Across Systematic Variations in T2-Weighted Magnetic Resonance Imaging Acquisition Parameters.在 T2 加权磁共振成像采集参数的系统变化中，对活体健康脑组织区域的放射组学特征的可重复性和稳健性进行前瞻性评估。
J Magn Reson Imaging. 2021 Sep;54(3):1009-1021. doi: 10.1002/jmri.27635. Epub 2021 Apr 16.
7
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers.放射组学分析预测晚期罕见癌症患者对 pembrolizumab 的反应。
J Immunother Cancer. 2021 Apr;9(4). doi: 10.1136/jitc-2020-001752.
8
Distinguishing granulomas from adenocarcinomas by integrating stable and discriminating radiomic features on non-contrast computed tomography scans.基于非增强 CT 扫描的稳定且具有鉴别能力的放射组学特征区分肉芽肿与腺癌。
Eur J Cancer. 2021 May;148:146-158. doi: 10.1016/j.ejca.2021.02.008. Epub 2021 Mar 17.
9
A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.基于 CT 的放射组学特征与晚期实体瘤免疫检查点抑制剂治疗反应相关。
Radiology. 2021 Apr;299(1):109-119. doi: 10.1148/radiol.2021200928. Epub 2021 Jan 26.
10
Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade.新型无创成像方法可识别接受免疫检查点抑制剂治疗的晚期非小细胞肺癌患者发生超进展性疾病的风险。
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-001343.
Zotero 插件